Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion

M L Cannon1, S S Glazier, L A Bauman

  • 1Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. mlcannon@wfubmc.edu

Journal of Neurosurgery
|January 5, 2002
PubMed

Insights

A pediatric patient experienced fatal metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion for sedation. This case highlights the risks of using propofol for extended sedation in children.

Area of Science:

  • Pediatric Critical Care Medicine
  • Neurocritical Care
  • Clinical Pharmacology

Background:

  • Severe closed head injury management in pediatric patients often requires prolonged sedation.
  • Continuous propofol infusion is a common strategy for sedation in pediatric intensive care units (PICUs).

Observation:

  • A 13-year-old girl with a severe head injury received a continuous propofol infusion (100 microg/kg/min) for 4 days.
  • The patient developed severe metabolic acidosis, rhabdomyolysis, acute renal failure, and cardiovascular collapse.
  • Despite maximal therapy, the patient's condition rapidly deteriorated, leading to multisystem organ failure.

Findings:

  • The patient exhibited severe high anion gap/low lactate metabolic acidosis unresponsive to treatment.
  • Rhabdomyolysis led to acute renal failure, and myocardial dysfunction presented with wide QRS complexes.
  • Death occurred due to myocardial collapse secondary to severe metabolic acidosis and organ failure.

Implications:

  • This case underscores the potential for severe adverse events, including metabolic acidosis and cardiovascular collapse, associated with prolonged propofol infusions in pediatric patients.
  • Alternative pharmacological agents should be considered for long-term sedation in pediatric populations to mitigate these risks.
  • Further research into the safe duration and dosage of propofol in pediatric critical care is warranted.

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...